Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735
Roche, a big pharmaceutical company, recently shared details from an early-stage trial with its oral anti-obesity candidate. Roche's oral anti-obesity candidate outperformed a similar candidate from Viking Therapeutics in terms of efficacy.
US FDA approves injectable version of Roche's multiple sclerosis therapy
The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple sclerosis.
Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug
RHHBY's data on experimental obesity drug, CT-996, disappoints investors on higher incidence of adverse events.
Roche Setback Is Big for Eli Lilly, Novo Nordisk as Obesity Drug Battle Ramps Up
The company's stock was falling after a report detailing side effects from its once-daily weight-loss pill.
Roche shares drop on side effects result in early-stage obesity pill trial
Shares in Roche fell on Thursday after an early-stage obesity pill candidate that carries high market hopes was linked to a high rate of temporary side effects in its initial test phase on humans.
Why Roche Holdings Stock Withered on Wednesday
The storied European pharmaceutical is forging ahead in its efforts to develop a weight loss treatment. Recent news from the lab about the medication is not encouraging, however.
Roche says early-stage obesity pill results were based on just six patients
Roche said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July were based on just six patients, underscoring the uncertainty of the development project.
Roche: Why I'm Not Concerned About Slight Sell-Off On Weight Loss Drug Safety Data
Roche stock has risen 22% since May due to promising GLP-1 agonist drug candidates, despite recent setbacks with CT-388's side effects. Roche's GLP-1 pipeline includes CT-388, CT-996 and CT-868, aiming to compete with Lilly and Novo's blockbuster weight loss drugs. Roche's core business remains strong, with Q2 2024 revenues up and guidance raised, providing a hedge against potential GLP-1 program failures.
The Zacks Analyst Blog Amazon, Roche, GE Aerospace, Canterbury Park and NVE
Amazon, Roche, GE Aerospace, Canterbury Park and NVE are included in this Analyst Blog.
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.
Roche Obtains Approval For its Rare Blood Disorder Drug in the EU
RHHBY gets approval for PiaSky for treating patients suffering from paroxysmal nocturnal hemoglobinuria in the EU.
All You Need to Know About Roche Holding (RHHBY) Rating Upgrade to Strong Buy
Roche Holding (RHHBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
